MEDICINOVA INC(NASDAQ:MNOV) stock News

MNOV Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

6 days ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

11 days ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

11 days ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

a year ago - By: BusinessInsider

MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024

a year ago - By: InvestorPlace

MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024

19 days ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

19 days ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

a month ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

a month ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

2 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

2 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

5 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

5 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

5 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

5 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

9 months ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

9 months ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

10 months ago - By: Benzinga - Mentions: ADSK ZTS VKTX PRCT

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

10 months ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

10 months ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

10 months ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

10 months ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

10 months ago - By: MediciNova, Inc.

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

10 months ago - By: MediciNova, Inc.